Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 6/20 | 0.74 |
| ▸ | MEN1 | O00255 | 5/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.63 |
| ▸ | HTT | P42858 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | CNR1 | P21554 | 1/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4423340 | 0.86 | EPHX2 (0.71) | NLRP3MEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL5106834 | 0.85 | NLRP3 (0.62) | NLRP3MEN1KMT2AALDH1A1HTT | |
| SCHEMBL5102413 | 0.85 | GAA (0.66) | NLRP3MEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL10750201 | 0.82 | KMT2A (0.77) | MEN1KMT2AALDH1A1HTTLMNA | |
| SCHEMBL8349809 | 0.82 | NLRP3 (0.58) | NLRP3 | |
| SCHEMBL5102126 | 0.81 | NLRP3 (0.76) | NLRP3MEN1KMT2AALDH1A1HTT | |
| SCHEMBL5107742 | 0.81 | NLRP3 (0.76) | NLRP3MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL18416957 | 0.81 | NLRP3 (0.78) | NLRP3 | |
| SCHEMBL10914448 | 0.80 | MEN1 (0.58) | NLRP3MEN1KMT2AALDH1A1HTT | |
| SCHEMBL10675526 | 0.80 | CNR1 (0.66) | MEN1KMT2AALDH1A1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7435729-B2 | Compounds and methods for modulation of estrogen receptors | SIGNAL PHARMACEUTICALS, LLC (US) | 2008-10-14 | — | — | US | disclosed |
| US-7279489-B2 | Compounds and methods for modulation of estrogen receptors | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-10-09 | — | — | US | disclosed |
| US-20050004360-A1 | Compounds and methods for modulation of estrogen receptors | SIGNAL PHARMACEUTICALS, INC. | 2005-01-06 | — | — | US | disclosed |
| EP-1468680-A2 | Using allosteric hemoglobin modifiers to decrease oxygen affinity in blood | Virginia Commonwealth University Intellectual Property Foundation, Inc. (US) | 2004-10-20 | — | — | EP | disclosed |
| US-20040082575-A1 | Compounds and methods for modulation of estrogen receptors | SIGNAL PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
| EP-1236711-B1 | Using allosteric hemoglobin modifiers to decrease oxygen affinity in blood | UNIV VIRGINIA COMMONWEALTH (US) | 2004-03-03 | — | — | EP | disclosed |
| US-6686351-B2 | PARTIALLY HYDROGENATED FUSED INDENE, NAPHTHALENE, ISOINDOLE, ISOQUINOLINE, BENZOAZEPINE AND BENZOCYCLOHEPTENE DERIVATIVES SUBSTITUTED BY A HYDROXY GROUP OR DERIVATIVE AND AN ARYL OR N-HETEROARYL GROUP | SIGNAL PHARMACEUTICALS, INC. | 2004-02-03 | — | — | US | disclosed |
| US-6593322-B1 | Methods are disclosed for modulating ER- beta in cell and/or tissues expressing the same, including cells and/ or tissue that preferentially ER- beta . Methods for treating estrogen-related conditions are also disclosed, including | SIGNAL PHARMACEUTICALS, INC. | 2003-07-15 | — | — | US | disclosed |
| EP-1322617-A1 | COMPOUNDS AND METHODS FOR MODULATION OF ESTROGEN RECEPTORS | SIGNAL PHARMACEUTICALS, INC. (US) | 2003-07-02 | — | — | EP | disclosed |
| US-20030087901-A1 | Compounds and methods for modulation of estrogen receptors | SIGNAL PHARMACEUTICALS, INC. | 2003-05-08 | — | — | US | disclosed |
| US-5705521-A | Use of allosteric hemoglobin modifiers in combination with radiation therapy to treat carcinogenic tumors | THE CENTER FOR INNOVATIVE TECHNOLOGY (US) | 1998-01-06 | — | — | US | disclosed |
| US-5677330-A | THERAPY HYPOXIA, HYPOTHERMIA, ISCHEMIC, WOUNDS, ULCERS, TISSUE TRANSPLANTS, SESPIS | THE CENTER FOR INNOVATIVE TECHNOLOGY (US) | 1997-10-14 | — | — | US | disclosed |
| US-5591892-A | CARBOXYALKOXYPHENYL SUBSTITUTED INDANES | CENTER FOR INNOVATIVE TECHNOLOGY (US) | 1997-01-07 | — | — | US | disclosed |
| US-5432191-A | Ring-substituted phenoxymethyl /or substituted methyl/ carboxylates | THE CENTER FOR INNOVATIVE TECHNOLOGY (US) | 1995-07-11 | — | — | US | disclosed |
| EP-0585366-A4 | USING ALLOSTERIC HEMOGLOBIN MODIFIERS TO DECREASE OXYGEN AFFINITY IN BLOOD. | CT FOR INNOVATIVE TECHNOLOGY (US) | 1994-03-17 | — | — | EP | disclosed |
| EP-0585366-A1 | USING ALLOSTERIC HEMOGLOBIN MODIFIERS TO DECREASE OXYGEN AFFINITY IN BLOOD | CENTER FOR INNOVATIVE TECHNOLOGY (US) | 1994-03-09 | — | — | EP | disclosed |
| US-5290803-A | Using allosteric hemoglobin modifiers to decrease oxygen affinity in blood | THE CENTER OF INNOVATIVE TECHNOLOGY (US) | 1994-03-01 | — | — | US | disclosed |
| US-5250701-A | 2-(Phthalomidomethylphenoxyalkanoic acid or ester; wound healing agents; antiischemic agents; blood storage; antidepressants; Alzheimer's disease; schizophrenia | CENTER FOR INNOVATIVE TECHNOLOGY (US) | 1993-10-05 | — | — | US | disclosed |
| US-5248785-A | Using allosteric hemoglobin modifiers to decrease oxygen affinity in blood | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1993-09-28 | — | — | US | disclosed |
| WO-1992020335-A1 | USING ALLOSTERIC HEMOGLOBIN MODIFIERS TO DECREASE OXYGEN AFFINITY IN BLOOD | CENTER FOR INNOVATIVE TECHNOLOGY (US) | 1992-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004360-A1 | Compounds and methods for modulation of estrogen receptors | ESRRB, ESR2, ESRRA | NLRP3 4703/4885MEN1 3529/4885KMT2A 1658/4885 |
| US-20030087901-A1 | Compounds and methods for modulation of estrogen receptors | ESRRB, ESRRA, ESR2 | NLRP3 4797/4885MEN1 2886/4885KMT2A 1405/4885 |
| US-20040082575-A1 | Compounds and methods for modulation of estrogen receptors | ESRRB, ESRRA, ESR2 | NLRP3 4760/4885MEN1 2906/4885KMT2A 1547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.